Back to top

Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Corvus Pharmaceuticals (CRVS – Research Report) today and set a price target...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Corvus Pharmaceuticals, Inc. (CRVS)